Table 2 Cox regression of mortality in overall hepatocellular carcinoma patients. (N = 156)

 Age (yrs), ≤65 vs. >65

100 vs. 56

0.613

 Gender, Female vs. Male

29 vs. 127

0.863

 BMI (kgs/m²), ≤22 (24) vs. >22 (24)

102 vs. 54

0.798

 Average dose (mg/kg), ≤35 vs. >35

97 vs. 59

0.848

 Cirrhosis, (-) vs. (+)

36 vs. 120

0.263

 CPC, score 5 vs. 6

81 vs. 75

0.015*

0.049*

0.492 (0.213–1.137)

 AE, (-) vs. (+)

57 vs. 99

<0.001*

0.015*

3.423 (1.274–9.199)

 Albumin (g/dL), ≤3.5 vs. >3.5

35 vs. 121

0.061

 Bilirubin (mg/dL), ≤1.3 vs. > 1.3

118 vs. 38

0.466

 INR, ≤1.2 vs. >1.2

116 vs. 40

0.321

 AST (IU/L), ≤34 vs. >34

25 vs. 130

0.181

 ALT (IU/L), ≤40 vs. >40

73 vs.83

0.036*

 Alk-p (IU/L), ≤126 vs. >126

87 vs.39

0.051

 AFP (ng/mL), ≤9 vs. > 9

34 vs. 122

<0.001*

0.003*

0.213 (0.078–0.583)

 Creatinine (mg/dL), ≤1.3 vs. > 1.3

138 vs. 18

0.188

 WBC (10³/dL), ≤105 vs. >105

136 vs.17

0.553

 Hb (gm/dL), ≤12 vs. >12

62 vs.94

0.115

 Platelet (10³/uL), ≤130 vs. >130

61 vs. 95

0.207

 HBV or HCV, (-) vs. (+)

21 vs. 135

0.873

 Tumor characters

 Tumor size, ≤5 vs. >5

82 vs. 74

0.046*

 Tumor numbers, ≤3 vs. >3

65 vs. 91

0.001*

0.009*

0.313 (0.131–0.747)

 Intra-hepatic vein, (-) vs. (+)

95 vs. 61

0.661

 Extra-hepatic metastases, (-) vs. (+)

81 vs. 75

0.388

 Mixed type (vein and metastases), (-) vs. (+)

136 vs. 20

0.517

 Sorafenib duration, cycle ≤ 1 vs. >1

75vs. 81

<0.001*

0.004*

3.694 (1.530–8.920)

 TACE (-) vs. (+)

89 vs. 67

0.031*

0.008*

3.197 (1.353–7.553)